FDA Approved Indications for this Orphan Drug:

Indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients

FDA Marketing Approval issued as of:
06/30/2016

Orphan Drug exclusivity ends on:
06/30/2023
Company Making and Marketing this drug:
AbbVie, Inc.

FDA Designation Date:
5/13/14

FDA Drug Designation:
Treatment of non-infectious intermediate, posterior, or pan-uveitis, or chronic non-infectious anterior uveitis